Catalyst

Slingshot members are tracking this event:

Incyte Corporation's (INCY) JAKAFI (Ruxolitinib) in Atopic dermatitis - PDUFA date under priority review extended by three months to September 21, 2021

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
INCY Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Jakafi, Ruxolitinib, Atopic Dermatitis